Next Article in Journal
Expression and Display of Glycoengineered Antibodies and Antibody Fragments with an Engineered Yeast Strain
Previous Article in Journal
From Anti-SARS-CoV-2 Immune Response to the Cytokine Storm via Molecular Mimicry
Review

Engineered mRNA and the Rise of Next-Generation Antibodies

1
Molecular Immunology Unit, Hospital Universitario Puerta de Hierro Majadahonda, 28220 Madrid, Spain
2
Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario12 de Octubre, 28041 Madrid, Spain
3
Immuno-Oncology and Immunotherapy Group, Instituto de Investigación Sanitaria 12 de Octubre (imas12), 28041 Madrid, Spain
*
Authors to whom correspondence should be addressed.
Academic Editor: Simon E. Hufton
Received: 10 August 2021 / Revised: 29 August 2021 / Accepted: 22 September 2021 / Published: 26 September 2021
Monoclonal antibodies are widely used as therapeutic agents in medicine. However, clinical-grade proteins require sophisticated technologies and are extremely expensive to produce, resulting in long lead times and high costs. The use of gene transfer methods for in vivo secretion of therapeutic antibodies could circumvent problems related to large-scale production and purification and offer additional benefits by achieving sustained concentrations of therapeutic antibodies, which is particularly relevant to short-lived antibody fragments and next-generation, Fc-free, multispecific antibodies. In recent years, the use of engineered mRNA-based gene delivery has significantly increased in different therapeutic areas because of the advantages it possesses over traditional gene delivery platforms. The application of synthetic mRNA will allow for the avoidance of manufacturing problems associated with recombinant proteins and could be instrumental in consolidating regulatory approvals for next-generation therapeutic antibodies. View Full-Text
Keywords: RNA; engineered mRNA; antibody fragments; multispecific antibodies; next-generation antibodies RNA; engineered mRNA; antibody fragments; multispecific antibodies; next-generation antibodies
MDPI and ACS Style

Sanz, L.; Álvarez-Vallina, L. Engineered mRNA and the Rise of Next-Generation Antibodies. Antibodies 2021, 10, 37. https://0-doi-org.brum.beds.ac.uk/10.3390/antib10040037

AMA Style

Sanz L, Álvarez-Vallina L. Engineered mRNA and the Rise of Next-Generation Antibodies. Antibodies. 2021; 10(4):37. https://0-doi-org.brum.beds.ac.uk/10.3390/antib10040037

Chicago/Turabian Style

Sanz, Laura, and Luis Álvarez-Vallina. 2021. "Engineered mRNA and the Rise of Next-Generation Antibodies" Antibodies 10, no. 4: 37. https://0-doi-org.brum.beds.ac.uk/10.3390/antib10040037

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop